Actinogen Trial Slows Alzheimer's Progression by 30%

Xanamem showed a 30% slowing of disease progression in patients over 75, though the full trial missed its primary endpoint.

Updated on Nov. 18, 2026 in Diseases

Isometric editorial illustration of a single oval capsule beside a simplified folded brain form in muted oxblood, teal, and cream, suggesting a drug's effect on cognitive decline.
Actinogen Medical reported its Xanamem treatment slowed Alzheimer's progression by 30% in patients over 75, though the full trial missed its primary endpoint. AI Illustration. Upload story photo >

Live Poll

Would you trust a new Alzheimer's drug that slowed decline in older patients?

Actinogen Medical reported that its Xanamem treatment slowed Alzheimer's disease progression by 30% among patients over 75 in the 36-week XanaMIA trial of 247 patients. The result did not reach statistical significance, and Xanamem failed to meet the primary endpoint across the full trial population.

Why it matters

Alzheimer's disease affects a large share of older Australians, and the findings suggest a possible benefit for older patients that warrants further study. The company has suspended further Phase 3 spending while it reviews the data, leaving the treatment's future uncertain.

The XanaMIA trial enrolled 247 patients over 36 weeks, with 40% of over-75 participants on Xanamem showing no progression compared with 22% on placebo. Whether this subgroup result would hold in a larger, prespecified study has not been determined.

The players

Actinogen Medical

Actinogen Medical is a Sydney-headquartered, publicly traded Australian biotechnology company developing Xanamem for Alzheimer's disease and depression.

The details

Xanamem is a once-daily oral treatment that inhibits the enzyme 11β-HSD1 to reduce excessive cortisol activity in the brain, and elevated cortisol has been linked to Alzheimer's progression and depression. No serious adverse events were attributed to the drug during the trial, and it has not received regulatory approval.

Timeline

  1. 36 weeks: duration of the XanaMIA trial for Alzheimer's patients.

  2. First quarter of 2027: next major milestone, when about 100 participants will have completed 24 weeks of treatment.

  3. Into 2028: expected duration of Actinogen's existing cash resources.

Clinical Context

The subgroup signal stands against the XanaMIA trial's primary endpoint, which the full population did not meet, so the over-75 finding is best treated as a hypothesis for future testing rather than an established effect. Its relevance depends on whether a larger trial confirms the benefit in older patients.

For now, Xanamem is not available as a treatment and has no regulatory approval, so patients and families cannot access it. Anyone affected by Alzheimer's should continue to rely on established care and discuss options with their doctor.

The takeaway

The results point to a possible benefit for older Alzheimer's patients, but the missed primary endpoint means larger trials are needed before the treatment can be judged. Readers should watch for Actinogen's 2027 milestone to see whether the signal holds.

What happens next

Actinogen expects its next major clinical milestone in the first quarter of 2027, when about 100 participants will have completed at least 24 weeks of treatment.

Further reading

Explore more on Alzheimer's research and treatments in Australia.

Source note: This article includes information reported by Proactiveinvestors NA.

Live Poll

Would you trust a new Alzheimer's drug that slowed decline in older patients?